Publications by authors named "Brian J Druker"

100Publications

Genomic markers of midostaurin drug sensitivity in FLT3 mutated and FLT3 wild-type acute myeloid leukemia patients.

Oncotarget 2020 Jul 21;11(29):2807-2818. Epub 2020 Jul 21.

Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.27656DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7381100PMC
July 2020

ERBB2/HER2 mutations are transforming and therapeutically targetable in leukemia.

Leukemia 2020 May 4. Epub 2020 May 4.

Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-020-0844-7DOI Listing
May 2020

Response and Resistance to BCR-ABL1-Targeted Therapies.

Cancer Cell 2020 Apr;37(4):530-542

Division of Hematology/Medical Oncology, Knight Cancer Insitute, Oregon Health & Science University, Portland, OR, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2020.03.006DOI Listing
April 2020

Functional characterization of two rare BCR-FGFR1 leukemias.

Cold Spring Harb Mol Case Stud 2020 04 1;6(2). Epub 2020 Apr 1.

Department of Medicine-Hematology, Stanford University, Stanford, California 94305, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1101/mcs.a004838DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7133745PMC
April 2020

Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.

N Engl J Med 2019 12;381(24):2315-2326

From the South Australian Health and Medical Research Institute and the University of Adelaide, Adelaide, SA, Australia (T.P.H., D.Y., D.M.R.); Memorial Sloan Kettering Cancer Center, New York (M.J.M., M.S.T., J.H.P.); University of Texas M.D. Anderson Cancer Center, Houston (J.E.C.); Kobe University Graduate School of Medicine, Kobe (H.M.), and the National Cancer Center Hospital East, Chiba (Y.M.) - both in Japan; Hôpital Saint-Louis, Paris (D.R.), and the University of Bordeaux, Bordeaux (F.-X.M.) - both in France; Dana-Farber Cancer Institute, Boston (D.J.D.); Sapienza University, Rome (M.B.); Singapore General Hospital, Singapore (Y.-T.G.); University of Michigan Comprehensive Cancer Center, Ann Arbor (M.T.); Universitätsklinikum Jena, Jena (A.H.), Charité Hospital, Berlin (P.C.), and the Department for Hematology-Oncology, Goethe University Hospital, Frankfurt am Main (F.L.) - all in Germany; University of Cardiff, Cardiff, United Kingdom (O.O.); Veterans Affairs Portland Health Care System (M.C.H.) and Oregon Health and Science University Knight Cancer Institute (M.C.H., B.J.D.), Portland; Hospital de la Princesa and Instituto de Investigación Sanitaria Princesa, Madrid (J.L.S.); Huntsman Cancer Institute, University of Utah, Salt Lake City (M.W.N.D.); Amsterdam University Medical Centers, VU University Medical Center, Amsterdam (J.J.W.M.J.); Novartis Pharma, Basel, Switzerland (D.H., Y.D., C.M., F.H.-P., K.G.V.); and Seoul St. Mary's Hematology Hospital, Catholic University of Korea, Seoul, South Korea (D.-W.K.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1902328DOI Listing
December 2019

Differentiation of leukemic blasts is not completely blocked in acute myeloid leukemia.

Proc Natl Acad Sci U S A 2019 12 21;116(49):24593-24599. Epub 2019 Nov 21.

Division of Hematology and Medical Oncology, Oregon Health & Science University Knight Cancer Institute, Portland, OR 97239;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1904091116DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6900505PMC
December 2019

Revisiting NTRKs as an emerging oncogene in hematological malignancies.

Leukemia 2019 11 24;33(11):2563-2574. Epub 2019 Sep 24.

Knight Cancer Institute, Oregon Health & Science University, Portland, OR, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-019-0576-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7410820PMC
November 2019

Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-Mediated Targeted Protein Degradation.

Cancer Res 2019 09 16;79(18):4744-4753. Epub 2019 Jul 16.

Department of Molecular, Cellular and Developmental Biology, Yale University, New Haven, Connecticut.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-19-1236DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6893872PMC
September 2019

The combination of NPM1, DNMT3A, and IDH1/2 mutations leads to inferior overall survival in AML.

Am J Hematol 2019 08 21;94(8):913-920. Epub 2019 Jun 21.

Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25517DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771683PMC
August 2019

Reply to N. Cerveira et al.

J Clin Oncol 2019 01 13;37(1):90-91. Epub 2018 Nov 13.

Ellin Berman, MD, Memorial Sloan Kettering Cancer Center, New York, NY; Brian J. Druker, MD, Oregon Health and Science Center, Portland, OR; and Richard Burwick, MD, Cedars Sinai Medical Center, Los Angeles, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.18.01004DOI Listing
January 2019

Functional genomic landscape of acute myeloid leukaemia.

Nature 2018 10 17;562(7728):526-531. Epub 2018 Oct 17.

Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41586-018-0623-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280667PMC
October 2018

Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia.

Leukemia 2018 09 6;32(9):2025-2028. Epub 2018 Aug 6.

Department of Cell, Development & Cancer Biology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41375-018-0225-7
Publisher Site
http://dx.doi.org/10.1038/s41375-018-0225-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6168939PMC
September 2018

Reply to D.M. Ross et al and V. Florou et al.

J Clin Oncol 2018 09 31;36(25):2660-2661. Epub 2018 May 31.

Ellin Berman, Memorial Sloan Kettering Cancer Center, New York, NY; Brian J. Druker, Oregon Health and Science Center, Portland, OR; and Richard Burwick, Cedars-Sinai Medical Center, Los Angeles, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.79.1806DOI Listing
September 2018

Automated decision tree to evaluate genetic abnormalities when determining prognostic risk in acute myeloid leukemia.

Haematologica 2018 08 22;103(8):e351-e355. Epub 2018 Mar 22.

Department of Cell, Developmental & Cancer Biology, Oregon Health and Science University, Portland, OR, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.190926DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6068037PMC
August 2018

Chronic Myelogenous Leukemia: Pregnancy in the Era of Stopping Tyrosine Kinase Inhibitor Therapy.

J Clin Oncol 2018 04 15;36(12):1250-1256. Epub 2018 Feb 15.

Ellin Berman, Memorial Sloan Kettering Cancer Center, New York, NY; Brian J. Druker, Oregon Health and Science Center, Portland, OR; and Richard Burwick, Cedars Sinai Medical Center, Los Angeles, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.77.2574DOI Listing
April 2018

EPHB4 is a therapeutic target in AML and promotes leukemia cell survival via AKT.

Blood Adv 2017 Sep 28;1(20):1635-1644. Epub 2017 Aug 28.

Division of Hematology, Department of Medicine, USC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA.

View Article

Download full-text PDF

Source
http://www.bloodadvances.org/lookup/doi/10.1182/bloodadvance
Publisher Site
http://dx.doi.org/10.1182/bloodadvances.2017005694DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728330PMC
September 2017

Novel Method Enabling the Use of Cryopreserved Primary Acute Myeloid Leukemia Cells in Functional Drug Screens.

J Pediatr Hematol Oncol 2017 10;39(7):e359-e366

*Knight Cancer Institute, Oregon Health and Science University ‡Howard Hughes Medical Institute, Portland, OR †Fred Hutchinson Cancer Research Center, Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MPH.0000000000000946DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5613078PMC
October 2017

Understanding cancer from the stem cells up.

Nat Med 2017 06;23(6):656-657

Howard Hughes Medical Institute Portland, Oregon, USA, and in the Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health &Science University, Portland, Oregon, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nm.4353DOI Listing
June 2017

Stability of patient-specific features of altered DNA replication timing in xenografts of primary human acute lymphoblastic leukemia.

Exp Hematol 2017 07 19;51:71-82.e3. Epub 2017 Apr 19.

Department of Biological Science, Florida State University, Tallahassee, FL; Center for Genomics and Personalized Medicine, Florida State University, Tallahassee, FL. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.exphem.2017.04.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5491210PMC
July 2017

Peter C. Nowell (1928-2016).

Proc Natl Acad Sci U S A 2017 05 17;114(18):4569-4570. Epub 2017 Apr 17.

Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97239;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1705526114DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5422792PMC
May 2017

Functional validation of the oncogenic cooperativity and targeting potential of tuberous sclerosis mutation in medulloblastoma using a MYC-amplified model cell line.

Pediatr Blood Cancer 2017 Oct 14;64(10). Epub 2017 Apr 14.

Department of Pediatrics, Doernbecher Children's Hospital, Papé Pediatric Research Institute, Oregon Health and Science University, Portland, Oregon.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pbc.26553DOI Listing
October 2017

Maternal, Fetal, and Neonatal Imatinib Levels With Treatment of Chronic Myeloid Leukemia in Pregnancy.

Obstet Gynecol 2017 05;129(5):831-834

Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine and Knight Cancer Institute, Division of Hematology and Medical Oncology, Oregon Health & Science University, and Howard Hughes Medical Institute, Portland, Oregon.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/AOG.0000000000001972DOI Listing
May 2017

Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid Leukemia.

Cell Rep 2017 03;18(13):3204-3218

Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97239, USA; Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland, OR 97239, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2017.03.018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5437102PMC
March 2017

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.

N Engl J Med 2017 03;376(10):917-927

From Abteilung Hämatologie-Onkologie, Universitätsklinikum Jena, Jena, Germany (A.H.); the Department of Medicine, University of Chicago, Chicago (R.A.L.); INSERM Centre d'Investigation Clinique 1402, Centre Hospitalier Universitaire de Poitiers, Poitiers, France (F.G.); Fred Hutchinson Cancer Research Center, Seattle (J.P.R.); Centre for Cancer Biology, SA Pathology, University of South Australia and University of Adelaide (S.B.), and the South Australian Health and Medical Research Institute and University of Adelaide (T.P.H.), Adelaide, SA, Australia; University of Bologna, Bologna, Italy (M.B.); the University of Utah Huntsman Cancer Institute, Salt Lake City (M.W.D.); the Hematology Department, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona (F.C.); Novartis, Basel, Switzerland (S.F., C.-E.O., H.D.M.); M.D. Anderson Cancer Center, Houston (H.K.); the University of Newcastle, Newcastle, United Kingdom (S.G.O.); and Knight Cancer Institute, Oregon Health and Science University and Howard Hughes Medical Institute, Portland (B.J.D.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1609324DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5901965PMC
March 2017

PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.

Cancer Lett 2016 12 5;383(2):220-229. Epub 2016 Oct 5.

Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY, 11439, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2016.09.025DOI Listing
December 2016

Concurrent STAT3, DNMT3A, and TET2 mutations in T-LGL leukemia with molecularly distinct clonal hematopoiesis of indeterminate potential.

Am J Hematol 2017 Jan 18;92(1):E6-E8. Epub 2016 Nov 18.

Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.24586DOI Listing
January 2017

Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia.

Sci Transl Med 2016 08;8(354):354ra114

Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97239, USA. Division of Pediatric Hematology and Oncology, Doernbecher Children's Hospital, Oregon Health & Science University, Portland, OR 97239, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/scitranslmed.aaf5309DOI Listing
August 2016

Ultrasensitive proteomic quantitation of cellular signaling by digitized nanoparticle-protein counting.

Sci Rep 2016 06 20;6:28163. Epub 2016 Jun 20.

Department of Biomedical Engineering, Oregon Health &Science University, Portland OR 97201, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/srep28163DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4913309PMC
June 2016

Durable Disease Control with MEK Inhibition in a Patient with NRAS-mutated Atypical Chronic Myeloid Leukemia.

Cureus 2015 Dec 17;7(12):e414. Epub 2015 Dec 17.

Knight Cancer Institute, Oregon Health & Science University ; Howard Hughes Medical Institute Investigator Program, Howard Hughes Medical Institute ; Division of Hematology & Medical Oncology, Oregon Health & Science University ; Department of Cell, Developmental & Cancer Biology, Oregon Health & Science University.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.414DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4725740PMC
December 2015

Cardio-Oncology: How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery.

Circulation 2015 Dec;132(23):2248-58

From Department of Medicine, Brigham and Women's Hospital, Boston, MA (A.M.B., G.D.D.); Vanderbilt-Ingram Cancer Center (C.L.A., J.M.), Cardiovascular Division (T.F., J.J.M.), and Cardio-Oncology Program (C.L.A., T.F., J.J.M.), Vanderbilt University School of Medicine, Nashville, TN; Department of Medicine, Washington University Medical Center, St. Louis, MO (B.D.H., J.M.); Dana-Farber Cancer Institute and Ludwig Center at Harvard, Harvard Medical School, Boston, MA (G.D.D.); and Knight Cancer Institute, Oregon Health & Science University and Howard Hughes Medical Institute, Portland, OR (B.J.D.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/CIRCULATIONAHA.115.010484DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4863699PMC
December 2015

Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.

Proc Natl Acad Sci U S A 2015 Sep 8;112(39):E5381-90. Epub 2015 Sep 8.

Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97239; Howard Hughes Medical Institute, Portland, OR 97239;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1515281112DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4593101PMC
September 2015

Therapeutically Targetable ALK Mutations in Leukemia.

Cancer Res 2015 Jun;75(11):2146-50

Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon. Department of Cell and Developmental Biology, Oregon Health and Science University, Portland, Oregon.

View Article

Download full-text PDF

Source
http://cancerres.aacrjournals.org/content/75/11/2146.full.pd
Web Search
http://cancerres.aacrjournals.org/cgi/doi/10.1158/0008-5472.
Publisher Site
http://dx.doi.org/10.1158/0008-5472.CAN-14-1576DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453002PMC
June 2015

Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance.

Cancer Res 2015 Mar 28;75(5):880-91. Epub 2014 Nov 28.

Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon. Department of Cell, Developmental and Cancer Biology, Oregon Health and Science University, Portland, Oregon.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-14-0573DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4348216PMC
March 2015

A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia.

Sci Transl Med 2014 Sep;6(252):252ra121

Howard Hughes Medical Institute, Programs in Gene Function and Expression and Molecular Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/scitranslmed.3009073DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4162097PMC
September 2014

Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia.

Leuk Res Rep 2014 1;3(2):67-9. Epub 2014 Aug 1.

Oregon Health and Sciences University, Knight Cancer Institute, Hematology and Medical Oncology, Portland, OR, USA ; Oregon Health and Sciences University, Knight Cancer Institute, Cell and Developmental Biology, Portland, OR, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lrr.2014.07.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4145163PMC
September 2014

PDGFRβ reverses EphB4 signaling in alveolar rhabdomyosarcoma.

Proc Natl Acad Sci U S A 2014 Apr 14;111(17):6383-8. Epub 2014 Apr 14.

Knight Cancer Institute, Oregon Health and Science University, Portland, OR 97239.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1403608111DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4035936PMC
April 2014

Janet Rowley (1925-2013).

Authors:
Brian J Druker

Nature 2014 Jan;505(7484):484

Knight Cancer Institute at Oregon Health & Science University, Portland, Oregon, and a Howard Hughes Medical Institute investigator. He shared the 2012 Japan Prize with Janet Rowley and Nicholas Lydon.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/505484aDOI Listing
January 2014

Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia.

Clin Cancer Res 2014 Apr 16;20(8):2092-103. Epub 2014 Jan 16.

Authors' Affiliations: Knight Cancer Institute; Division of Hematology & Medical Oncology; Departments of Cell and Developmental Biology and Molecular and Medical Genetics, Oregon Health and Science University; Howard Hughes Medical Institute, Portland, Oregon; Oncotide Pharmaceuticals, Research Triangle Park; Duke University Medical Center, Durham, North Carolina; and Division of Oncology, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/content/20/8/2092.full
Web Search
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-13-2575DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3989420PMC
April 2014

Comparison of methods to identify aberrant expression patterns in individual patients: augmenting our toolkit for precision medicine.

Genome Med 2013 29;5(11):103. Epub 2013 Nov 29.

Knight Cancer Institute, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA ; Oregon Clinical and Translational Research Institute, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA ; Division of Bioinformatics and Computational Biology, DMICE, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/gm509DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3971350PMC
May 2014

Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins.

Proc Natl Acad Sci U S A 2013 Nov 11;110(48):19519-24. Epub 2013 Nov 11.

Knight Cancer Institute, Howard Hughes Medical Institute, and Departments of Biochemistry and Molecular Biology and Cell and Developmental Biology, Oregon Health and Sciences University, Portland, OR 97239.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1319583110DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3845150PMC
November 2013

Mouse model of intrahepatic cholangiocarcinoma validates FIG-ROS as a potent fusion oncogene and therapeutic target.

Proc Natl Acad Sci U S A 2013 Nov 23;110(48):19513-8. Epub 2013 Oct 23.

Cancer Biology and Genetics Program and Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY 10065.

View Article

Download full-text PDF

Source
http://www.pnas.org/cgi/doi/10.1073/pnas.1311707110
Publisher Site
http://dx.doi.org/10.1073/pnas.1311707110DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3845141PMC
November 2013

Kinase inhibitor therapy in CML: it's what's inside that counts.

Oncotarget 2013 Sep;4(9):1332-3

Howard Hughes Medical Institute; Division of Hematology and Medical Oncology, Oregon Health and Science University, Knight Cancer Institute, Portland, OR.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3824533PMC
http://dx.doi.org/10.18632/oncotarget.1271DOI Listing
September 2013

KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors.

Cancer Res 2013 Sep 25;73(18):5775-86. Epub 2013 Jul 25.

Authors' Affiliations: OHSU Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon; Howard Hughes Medical Institute, Chevy Chase, Maryland; Huntsman Cancer Institute; Division of Hematology and Hematologic Malignancies, The University of Utah, Salt Lake City, Utah; Novartis Institutes for BioMedical Research, Basel, Switzerland; and Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-13-1318DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3894913PMC
September 2013

Imatinib and Dasatinib Inhibit Hemangiosarcoma and Implicate PDGFR-β and Src in Tumor Growth.

Transl Oncol 2013 Apr 1;6(2):158-68. Epub 2013 Apr 1.

Veterinary Clinical Sciences, University of Minnesota, St Paul, MN ; Masonic Cancer Center, University of Minnesota, Minneapolis, MN.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3610544PMC
http://dx.doi.org/10.1593/tlo.12307DOI Listing
April 2013

HitWalker: variant prioritization for personalized functional cancer genomics.

Bioinformatics 2013 Feb 9;29(4):509-10. Epub 2013 Jan 9.

Knight Cancer Institute, Oregon Health and Science University, Portland, OR 97239, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/bioinformatics/btt003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3570211PMC
February 2013